Company Overview

NovaBay Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical and specialty healthcare company historically focused on developing and commercializing non-antibiotic antimicrobial products for ophthalmology, dermatology, and wound care. The company’s core competency has been the development of products based on its proprietary pure hypochlorous acid (HOCl) technology, which is designed to provide broad-spectrum antimicrobial activity while remaining well tolerated for human use.

NovaBay’s primary revenue historically came from branded, prescription, and over-the-counter healthcare products, most notably Avenova®, an eyelid and eyelash hygiene product, and NeutroPhase®, a wound care and skin cleansing solution. The company primarily served eye care professionals, hospitals, wound care clinics, and consumers through physician recommendations. NovaBay was founded in the early 2000s and evolved from a development-stage pharmaceutical company into a commercial-stage company before significantly restructuring its business through asset divestitures. Public disclosures indicate that the company’s operating focus has narrowed substantially following the sale of key product assets, materially changing its business profile.

Business Operations

Historically, NovaBay operated through a single reporting segment focused on the development, manufacturing oversight, and commercialization of antimicrobial healthcare products. Revenue generation was primarily driven by product sales of Avenova® through distributors and direct-to-consumer channels, as well as sales of NeutroPhase® into clinical and institutional settings. Manufacturing was largely outsourced, while the company retained control over formulation, intellectual property, regulatory strategy, and commercialization.

In recent SEC filings, NovaBay disclosed the divestiture of its primary operating assets, including the Avenova® product line, resulting in a substantial reduction in active commercial operations. Following these transactions, the company reported limited ongoing revenue-generating activities and reduced headcount. Data regarding any replacement operating businesses or new revenue streams is inconclusive based on available public sources.

Strategic Position & Investments

NovaBay’s historical strategy centered on leveraging its proprietary HOCl-based technology platform to address unmet needs in infection control without contributing to antibiotic resistance. Growth initiatives previously included expanding Avenova® into broader eye care channels and exploring additional dermatology and wound care indications for its technology.

Following the divestiture of its principal assets, NovaBay’s strategic direction shifted toward preserving shareholder value and evaluating strategic alternatives. Public disclosures reference cost reductions, balance sheet management, and the assessment of potential transactions or new business opportunities. No material acquisitions, controlling investments, or new operating subsidiaries have been conclusively verified in public filings subsequent to the asset sales, and future strategic plans remain limited in disclosed detail.

Geographic Footprint

NovaBay Pharmaceuticals is headquartered in United States, with historical operations primarily concentrated in North America. Its products were sold predominantly in the U.S. market, with limited international exposure through distributors and licensing arrangements in select foreign markets.

The company has not disclosed significant owned international infrastructure, manufacturing facilities, or large-scale overseas subsidiaries. Following the reduction in operating activities, NovaBay’s geographic footprint appears largely limited to corporate and administrative presence in the U.S., with no verified evidence of material international operations currently in place.

Leadership & Governance

NovaBay is led by an executive team and board responsible for overseeing the company through its post-divestiture phase, focusing on governance, financial stewardship, and strategic evaluation. Leadership disclosures emphasize operational discipline, capital preservation, and compliance with public company obligations rather than aggressive commercial expansion.

Key executives and leaders include:

• Justin Hall – Chief Executive Officer
• Steven R. Simpson – Chief Financial Officer
• Thomas J. von Gremp – Chairman of the Board
• Paul B. Young – Director

The leadership philosophy, as reflected in public filings, prioritizes shareholder value, prudent financial management, and careful consideration of strategic alternatives in light of the company’s significantly reduced operating scale.